References
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Botanical drug development guidance for industry, revision 1. [ cited 2020 June 22]. Available from: https://www.fda.gov/media/93113/download
- Lal R. Botanical drug review. FDA/CDER SBIA Chronicles; 2015 Nov 17 [cited 2020 June 22]. Available from: https://wwwfdagov/Drugs/InformationOnDrugs/ucm079436htm
- Schmidt B, Ribnicky DM, Poulev A, et al. A natural history of botanical therapeutics. Metabolism. 2008 July;57(7 Suppl 1):S3–9.
- US Food and Drug Administration. Drugs@FDA glossary of terms. 2017 [cited 2020 June 22]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms
- Wu C, Lee S-L, Taylor C, et al. Scientific and regulatory approach to botanical drug development: a U.S. FDA perspective. J Nat Prod. 2020;83(2):552–562.
- United States Congress. Dietary supplement health and education act of 1994” (DSHEA), Public law 103-417. [ cited 2020 June 22]. Available from: https://ods.od.nih.gov/About/dshea_wording.aspx
- Enioutina EY, Salis ER, Job KM, et al. Herbal medicines: challenges in the modern world. Part 5. status and current directions of complementary and alternative herbal medicine worldwide. Expert Rev Clin Pharmacol. 2017 Mar;10(3):327–338.
- Gottlieb S U.S. Department of Health and Human Services, Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s new efforts to strengthen regulation of dietary supplements by modernizin and reforming FDA’s oversight; 2019 Feb 11 [cited 2020 May 1]. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-agencys-new-efforts-strengthen-regulation-dietary
- Barnes J. Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand. Expert Rev Clin Pharmacol. 2016 Mar;25:1–47.
- Sammons HM, Gubarev MI, Krepkova LV, et al. Herbal medicines: challenges in the modern world. Part 2. European Union and Russia. Expert Rev Clin Pharmacol. 2016 Aug;9(8):1117–1127.
- Teng L, Zu Q, Li G, et al. Herbal medicines: challenges in the modern world. Part 3. China and Japan. Expert Rev Clin Pharmacol. 2016 Sept;9(9):1225–1233.
- Job KM, Kiang TK, Constance JE, et al. Herbal medicines: challenges in the modern world. Part 4. Canada and United States. Expert Rev Clin Pharmacol. 2016 Dec;9(12):1597–1609.
- Dobos GJ, Tan L, Cohen MH, et al. Are national quality standards for traditional Chinese herbal medicine sufficient?: Current governmental regulations for traditional Chinese herbal medicine in certain Western countries and China as the Eastern origin country. Complement Ther Med. 2005;13(3):183–190.
- Salim A, Chin YW, Kinghorn A. Drug discovery from plants. In: Ramawat K MJ, editor. Bioactive molecules and medicinal plants. Berlin, Heidelberg: Springer; 2008. p. 1–25. ISBN: 978-3-540-75600-3. https://doi.org/http://doi.org/10.1007/978-3-540-74603-4_1
- Butler MS, Robertson AAB, Cooper MA. Natural product and natural product derived drugs in clinical trials. Nat Prod Rep. 2014;31(11):1612–1661.
- Taylor L Plant based drugs and medicines. 2017 [cited 2020 June 22]. Available from: http://www.rain-tree.com/plantdrugs.htm#.W1DvXYWcHVj
- Patridge E, Gareiss P, Kinch MS, et al. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov Today. 2016 Feb 1;21(2):204–207.
- Plodkowski RA, McGarvey ME, Huribal HM, et al. SGLT2 inhibitors for type 2 diabetes mellitus treatment. Fed Pract. 2015;32(Suppl11):8S–15S.
- Ko JK, Auyeung KK. Target-oriented mechanisms of novel herbal therapeutics in the chemotherapy of gastrointestinal cancer and inflammation. Curr Pharm Des. 2013;19(1):48–66.
- Schmidt BM, Ribnicky DM, Lipsky PE, et al. Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol. 2007 July;3(7):360–366.
- Paladin Labs Inc. Product monograph. PrVEREGEN®, Sinecatechins Ointment, 10% w/w,Topical Treatment for Genital Warts. [ cited 2020 June 22]. Available from: http://www.paladin-labs.com/our_products/Veregen-PM-En.pdf?ver=3.0
- MYTESI® (crofelemer) delayed-release tablets, for oral use. Initial U.S. Approval: 2012 [cited 2020 June 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202292s006lbl.pdf
- US Food and Drug Administration. Botanical drug development guidance for industry, U.S. department of health and human services. In: Center for Drug Evaluation and Research (CDER). editor. U.S. Department of Health and Human Services; 2006.
- US Food & Drug Administration. Over-the-counter (OTC), ingredient references, and other regulatory information, listing of OTC active ingredients. 2010, federal register notices. [ cited 2020 June 22]. Available from: https://www.fda.gov/media/75758/download
- Gahche JJ, Bailey RL, Potischman N, et al. Federal monitoring of dietary supplement use in the resident, civilian, noninstitutionalized US population: national health and nutrition examination survey. J Nutr. 2018;148(suppl_2):1436S–1444S.
- Gahche J, Bailey R, Burt V, et al. Dietary supplement use among U.S. adults has increased since NHANES III (1988–1994). NCHS Data Brief. 2011;61:1–8.
- Gardiner P, Kemper KJ. Herbs in pediatric and adolescent medicine. Pediatr Rev. 2000 Feb;21(2):44–57.
- Wang C, Preisser J, Chung Y, et al. Complementary and alternative medicine use among children with mental health issues: results from the national health interview survey. BMC Complem Altern Med. 2018 Aug 29;18(1):241.
- Schempp CM, Schopf E, Simon JC. Plant-induced toxic and allergic dermatitis (phytodermatitis). Hautarzt. 2002 Feb;53(2):93–97.
- Stournaras E, Tziomalos K. Herbal medicine-related hepatotoxicity. World J Hepatol. 2015 Sept 8;7(19):2189–2193.
- Bunchorntavakul C, Reddy KR. Herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013 Jan;37(1):3–17.
- Lin NH, Yang HW, Su YJ, et al. Herb induced liver injury after using herbal medicine: a systemic review and case-control study. Medicine (Baltimore). 2019 Mar;98(13):e14992.
- Navarro VJ, Khan I, Bjornsson E, et al. Liver injury from herbal and dietary supplements. Hepatology. 2017 Jan;65(1):363–373.
- Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol. 2015;6:72.
- Revol B, Gautier-Veyret E, Arrive C, et al. Pharmacokinetic herb-drug interaction between ginger and crizotinib. Br J Clin Pharmacol. 2019 Jan;30. [Epub ahead of print].
- Laube R, Liu K. An unwanted complement: rare case of potential liver injury induced by an interaction between ginseng and atorvastatin. Br J Clin Pharmacol. 2019;85(7):1612–1613.
- Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ. Understanding drug interactions with St John’s wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol. 2019 Jan;71(1):129–138.
- Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000 July;294(1):88–95.
- Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos. 2004 May;32(5):512–518.
- Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003 Sept 17;290(11):1500–1504.
- Gurley BJ. Pharmacokinetic herb-drug interactions (Part 1): origins, mechanisms, and the impact of botanical dietary supplements. Planta Med. 2012 May 9;78(13):1478–1489.
- Brewer CT, Chen T. Hepatotoxicity of herbal supplements mediated by modulation of cytochrome P450. Int J Mol Sci. 2017 Nov 8;18(11). DOI:https://doi.org/10.3390/ijms18112353
- Albassam AA, Markowitz JS. An appraisal of drug-drug interactions with green tea (Camellia sinensis). Planta Med. 2017 Apr;83(6):496–508.
- Liu M-Z, Zhang Y-L, Zeng M-Z, et al. Pharmacogenomics and herb-drug interactions: merge of future and tradition. Evid Based Complement Alternat Med. 2015;2015:321091.
- U.S. Food and Drug Administration. Tainted products marketed as dietary supplements_CDER. [ cited 2020 June 22]. Available from: https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?filter=&sortColumn=1d⋅tainted_supplements_cder&page=1
- Tucker J, Fischer T, Upjohn L, et al. Unapproved pharmaceutical ingredients included in dietary supplements associated with US food and drug administration warnings. JAMA Network Open. 2018;1(6):e183337–e183337.
- Cohen PA, The FDA. Adulterated supplements—dereliction of duty. JAMA Network Open. 2018;1(6):e183329–e183329.
- U.S. Food and Drug Administration., Import Alert 54-1. Detention without physical examination of dietary supplements and bulk dietary ingredients containing ephedrine alkaloids from all countries. [ cited 2020 June 22]. Available from: https://www.accessdata.fda.gov/cms_ia/importalert_144.html#:~:text=A%20detained%20product%20or%20bulk,is%20free%20of%20ephedrine%20alkaloids. Published 2020 Sept 1. Available from: https://www.accessdata.fda.gov/cms_ia/importalert_144.html
- Institute of Medicine. Dietary reference intakes: a risk assessment model for establishing upper intake levels for nutrients. Washington (DC): The National Academies Press; 1998.
- National Institute of Health, Office of Dietary Supplements; Health Information. Daily values. [ cited 2020 June 22]. Available from: https://ods.od.nih.gov/HealthInformation/dailyvalues.aspx
- Institute of Medicine. Standing committee on the scientific evaluation of dietary reference intakes and its panel on folate, other B vitamins, and choline. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin b12, pantothenic acid, biotin, and choline. Washington (DC): National Academies Press (US); 1998.
- Hathcock JN, Griffiths JC Vitamin and mineral safety. In: Mackay D, Wong A, Nguyen Heditors. Science Behind the Supplements. 3rd ed. Washington (DC): Council for Responsible Nutrition (CRN); 2014. [cited 2020 June 22]. Available from: https://www.crnusa.org/sites/default/files/files/resources/CRN-SafetyBook-3rdEdition-2014-fullbook.pdf
- WebMD. Vitamins and supplements. Riboflavin. Side effects and Safety. 2019 [cited 2020 June 22]. Available from: https://www.webmd.com/vitamins/ai/ingredientmono-957/riboflavin
- WebMD. Vitamins and Supplements. Vitamin B12. Side Effects and Safety. 2019 [cited 2020 June 22]. Available from: https://www.webmd.com/vitamins/ai/ingredientmono-926/vitamin-b12
- WebMD. Vitamins and Supplements. Pyridoxime (Vitamin B6). Side Effects and Safety; 2019 [cited 2020 June 22]. Available from: https://www.webmd.com/vitamins/ai/ingredientmono-934/pyridoxine-vitamin-b6
- Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochem J. 2011 Aug 1;437(3):357–372.
- Combs GF, McClung JP. Fundamental aspects in nutrition and health. London: Academic press; 2017.
- Toxicology Data Network. Hazardous Substances Data Bank. Vitamin B1; 2019 [cited 2020 June 22]. Available from: https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+220
- Aurich S, Simon JC, Treudler R. A case of anaphylaxis to intramuscular but not to oral application of thiamine (Vitamin B1). Iran J Allergy Asthma Immunol. 2018 Feb;17(1):94–96.
- Toxicology Data Network. Hazardous substances data bank, riboflavin. 2019. [cited 2020 June 22]. Available from: https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+817
- Ross AC, Taylor CL, Yaktine AL Committee to review dietary reference intakes for vitamin D and calcium. Institute of Medicine., National Academies Press (US). Washington (DC) 2011 [cited 2020 June 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK56070/
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 July;96(7):1911–1930.
- National Institute of Health. Dietary supplements label database, labeling daily values. 2019 [updated 2019; cited 2019; cited 2020 June 22]. Available from: https://www.dsld.nlm.nih.gov/dsld/dailyvalue.jsp
- Ronis MJJ, Pedersen KB, Watt J. Adverse effects of nutraceuticals and dietary supplements. Annu Rev Pharmacol Toxicol. 2018 Jan;6(58):583–601.
- Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington (DC): National Academies Press (US); 2000. [cited 2020 June 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK225483/
- Yoo SJ, Walfish SL, Atwater JB, et al. Factors to consider in setting adequate overages of vitamins and minerals in dietary supplements. Pharmacopeial Forum. 2016 Jan;1:42.
- Bian ZX, Li YP, Moher D, et al. Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology. Zhong Xi Yi Jie He Xue Bao. 2006 Mar;4(2):120–129.
- Loyeung B, Lee J, Michaeil C, et al. An experimental study in distinguishing an authentic herbal substance from sham herbal substances. Complement Ther Med. 2018 Aug 1;39:92–96.
- Brantley SJ, Gufford BT, Dua R, et al. Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction. CPT Pharmacometrics Syst Pharmacol. 2014;3(3):e107–e107.
- Gurley BJ, Yates CR, Markowitz JS. “ … not intended to diagnose, treat, cure or prevent any disease.” 25 years of botanical dietary supplement research and the lessons learned. Clin Pharmacol Ther. 2018 Sept;104(3):470–483.
- Kuszak AJ, Hopp DC, Williamson JS, et al. Approaches by the US National Institutes of Health to support rigorous scientific research on dietary supplements and natural products. Drug Test Anal. 2016;8(3–4):413–417.
- McCullagh M, Pereira CAM, Yariwake JH. Use of ion mobility mass spectrometry to enhance cumulative analytical specificity and separation to profile 6-C/8-C-glycosylflavone critical isomer pairs and known-unknowns in medicinal plants. Phytochem Anal. 2019 July;30(4):424–436.
- Gardiner P, Phillips RS, Kemper KJ, et al. Dietary supplements: inpatient policies in US children’s hospitals. Pediatrics. 2008 Apr;121(4):e775–81.
- Sarker SD, Nahar L. Hyphenated techniques and their applications in natural products analysis. Methods Mol Biol. 2012;864:301–340.
- National Institutes of Health. Center of Excellence for Natural Product Drug Interaction Research, National Center for Complementary and Integrative Health (NCCIH) 2019 [cited 2020 June 22]. Available from: https://www.nccih.nih.gov/news/events/summary-webinar-rfa-at-20-002
- Washington State University. Center of excellence for natural product-drug interaction research (NaPDI) 2020 [cited 2020 Apr]. Available from: https://napdicenter.org/
- Gurley BJ. Clinical pharmacology and dietary supplements: an evolving relationship. Clin Pharmacol Ther. 2010 Feb;87(2):235–238.